224 related articles for article (PubMed ID: 32354261)
1. Cost-effectiveness analysis of fruquintinib as third-line treatment for patients with metastatic colorectal cancer.
Zhang PF; Xie D; Li Q
Tumori; 2020 Oct; 106(5):400-405. PubMed ID: 32354261
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China.
Guan X; Li H; Xiong X; Peng C; Wang N; Ma X; Ma A
J Med Econ; 2021; 24(1):339-344. PubMed ID: 33571036
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China.
Peng Z; Hou X; Huang Y; Xie T; Hua X
BMC Cancer; 2020 Oct; 20(1):990. PubMed ID: 33050905
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of capecitabine plus bevacizumab versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer from Chinese societal perspective.
Zhang PF; Wen F; Zhou J; Huang JX; Zhou KX; Wu QJ; Wang XY; Zhang MX; Liao WT; Li Q
Clin Transl Oncol; 2020 Jan; 22(1):103-110. PubMed ID: 31062173
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States.
Cho SK; Hay JW; Barzi A
Clin Colorectal Cancer; 2018 Dec; 17(4):e751-e761. PubMed ID: 30228027
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study.
Xu RH; Li J; Bai Y; Xu J; Liu T; Shen L; Wang L; Pan H; Cao J; Zhang D; Fan S; Hua Y; Su W
J Hematol Oncol; 2017 Jan; 10(1):22. PubMed ID: 28103904
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial.
Wang H; Huang L; Gao P; Zhu Z; Ye W; Ding H; Fang L
BMJ Open; 2020 Feb; 10(2):e030738. PubMed ID: 32051297
[TBL] [Abstract][Full Text] [Related]
9. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis.
Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; El-Rayes BF; Flowers CR
J Clin Oncol; 2015 Apr; 33(10):1112-8. PubMed ID: 25691669
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of fruquintinib in Chinese patients with refractory metastatic colorectal cancer.
Huang Z; Zhou L; Zheng H; Zhan M
Int J Clin Pharm; 2024 Apr; ():. PubMed ID: 38642249
[TBL] [Abstract][Full Text] [Related]
11. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial.
Li J; Qin S; Xu RH; Shen L; Xu J; Bai Y; Yang L; Deng Y; Chen ZD; Zhong H; Pan H; Guo W; Shu Y; Yuan Y; Zhou J; Xu N; Liu T; Ma D; Wu C; Cheng Y; Chen D; Li W; Sun S; Yu Z; Cao P; Chen H; Wang J; Wang S; Wang H; Fan S; Hua Y; Su W
JAMA; 2018 Jun; 319(24):2486-2496. PubMed ID: 29946728
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma in the United States.
Peng Y; She Z; Peng L; Liu Q; Yi L; Luo X; Li S; Wang L; Qin S; Wan X; Tan C
Adv Ther; 2021 Dec; 38(12):5710-5720. PubMed ID: 34693504
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer.
Patel KK; Stein S; Lacy J; O'Hara M; Huntington SF
JAMA Netw Open; 2021 Jan; 4(1):e2033441. PubMed ID: 33433598
[TBL] [Abstract][Full Text] [Related]
14. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
[TBL] [Abstract][Full Text] [Related]
15. A comparison of regorafenib and fruquintinib for metastatic colorectal cancer: a systematic review and network meta-analysis.
Jing Z; Rui Z; Binglan Z
J Cancer Res Clin Oncol; 2019 Sep; 145(9):2313-2323. PubMed ID: 31278474
[TBL] [Abstract][Full Text] [Related]
16. Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in the FRESCO trial.
Qin S; Li J; Bai Y; Deng Y; Yang L; Xu RH; Zhong H; Chen Z; Pan H; Guo W; Shu Y; Xu J; Peng C; Chen Y; Li H; Wang N; Guo X; Peng M; Fan S; Shen L
Future Oncol; 2021 May; 17(15):1923-1931. PubMed ID: 33563040
[TBL] [Abstract][Full Text] [Related]
17. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system.
Zhu C; Han G; Wu B
BMC Health Serv Res; 2023 Oct; 23(1):1083. PubMed ID: 37821934
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
Graham CN; Hechmati G; Hjelmgren J; de Liège F; Lanier J; Knox H; Barber B
Eur J Cancer; 2014 Nov; 50(16):2791-801. PubMed ID: 25219451
[TBL] [Abstract][Full Text] [Related]
20. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]